Valuable product pipeline

Our research efforts today are focusing on developing vaccines and antibodies that address unmet medical needs and infectious diseases. Our research efforts are bolstered by our range of technologies, which play a critical role in our development programs. The following pages discuss key developments relating to our discovery programs, as well as providing key areas of focus.

Crucell currently has vaccine and protein programs in various stages of development. Most of these are based on Crucell’s innovative PER.C6^® production technology. Core programs include vaccines against influenza, tuberculosis, malaria and antibody products against rabies and influenza.

Crucell’s current pipeline programs comprise:

Vaccines in development:

• Yellow Fever vaccine
• Influenza seasonal vaccine
• Tuberculosis vaccine
• Malaria vaccine
• Ebola and Marburg vaccine
• HIV vaccine

Human antibodies in development:

• Rabies antibody combination
• Influenza antibodies H1 and H5
• Hepatitis C antibody combination

Other:

• Factor V^L/C

Product Pipeline

1. Developed by sanofi pasteur using PER.C6®; 2. Partnered with Aeras; 3. Partnered with NIH (Ad 35) & MVI (Ad35 + Ad26); 4. Partnered with Harvard; 5. Partnered with sanofi pasteur

 

                                                                                                                                                           

Products in a focused pipeline

As part of our product development program, we investigate many different product candidates.

Our discovery programs include a number of potential products that are in an early stage of development. The decision to pursue development of these products and add them to our product pipeline is dependent on stringent evaluation and selection.

Key developments relating to our pipeline over the year 2008:

• Successful Phase II results of studies in the US and Philippines of our rabies antibody combination, showing safety and tolerability. Third Phase II study in India in  progress.

• Encouraging results from the Phase I Ad35 tuberculosis vaccine study, showing that CD8 immune responses are considerably higher than ever seen in a tuberculosis vaccine study. Program entered Phase II clinical testing.

• Alternative adenovirus serotypes like Ad26 and Ad35 using Crucell’s AdVac®/PER.C6® technologies were used to express protein of SIV (HIV-like virus). Study showed strong T-cell immune response and  provides protection against SIV. Malaria and TB vaccines in development using Ad26 and Ad35.

• Crucell’s monoclonal antibodies (mAb) against influenza strongly outperforms the anti-influenza drug oseltamivir in pre-clinical tests.